Liquid Buccal Mucosa Graft Urethroplasty (LBMG)
Primary Purpose
Urethral Stricture
Status
Unknown status
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
DVIU treated with liquid buccal mucosal graft
Sponsored by
About this trial
This is an interventional treatment trial for Urethral Stricture
Eligibility Criteria
Inclusion Criteria:
- Male >18 years of age
- bulbar urethral stricture
- bladder neck contracture
Exclusion Criteria:
- <18 years old
- developmental delay
- incarcerated individuals,
- history of prior urethroplasty
- history of cerebrovascular diseases (prior stroke, MI)
- history of deep vein thrombosis
- history of pulmonary embolism
- history of clotting disorders
- factor 5 Leiden
- antiphospholipid antibody syndrome
- prothrombin gene mutation
- protein S deficiency
- protein C deficiency
- dysfibrinogenemia
- polycythemia vera
- essential thrombocytosis
- untreated malignancy
- hypercoagulable state
Sites / Locations
- SUNY Upstate Medical University
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
liquid buccal mucosa graft
Arm Description
DVIU treated with liquid buccal mucosal graft; endoscopic injection of morcellated buccal mucosal graft mixed with fibrin glue
Outcomes
Primary Outcome Measures
Voiding Surgical Outcomes: Stricture Recurrence
The ultimate outcome of this procedure is number of patients successfully treated without need for re-intervention (such as need for urethral dilation, endoscopic manipulation or open reconstruction). Recurrence of stricture will be reported as number of events. To detect stricture recurrence, patients will be monitored with: peak urine flow (milliliters per second) and post-void residuals (milliliters) and will be assessed post- operatively at every visit up to three years Flexible cystoscopy will be offered to patients at one year follow up or at any time point if there is suspicion of stricture recurrence based on patients complaints (reported as number of recurrences).
Secondary Outcome Measures
Immediate Perioperative Outcomes
This is a composite outcome measure consisting of the following measures: duration of surgery (time in minutes), immediate postoperative complications: bleeding requiring blood transfusion (units of transfused blood), cerebrovascular complications reported as number of events (stroke, myocardial infarctions, pulmonary emboli) , problems with anesthesia (inability to extubate, need to re-intubate reported as number of each events), allergic reactions including anaphylaxis (number) and, duration of hospital stay (days).
Short-term Postoperative Outcomes
This is a composite outcome measure consisting of the following measures: Urinary Tract Infection (number of infections requiring treatment), Sepsis (number of events), unscheduled ER visits (number), readmissions for hospital stay (number of events).
Patient Satisfaction
Global Response Assessment questionnaire will be given to patients at every visit to assess overall satisfaction with the procedure.
Full Information
NCT ID
NCT03061344
First Posted
August 19, 2016
Last Updated
February 17, 2017
Sponsor
State University of New York - Upstate Medical University
1. Study Identification
Unique Protocol Identification Number
NCT03061344
Brief Title
Liquid Buccal Mucosa Graft Urethroplasty
Acronym
LBMG
Official Title
Endoscopic Buccal Mucosal Graft Urethroplasty or Bladder Neck Reconstruction
Study Type
Interventional
2. Study Status
Record Verification Date
February 2017
Overall Recruitment Status
Unknown status
Study Start Date
February 2017 (Anticipated)
Primary Completion Date
October 2019 (Anticipated)
Study Completion Date
October 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
State University of New York - Upstate Medical University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Study Objectives The current definitive treatment options for urethral stricture disease include endoscopic urethrotomy known as Direct Vision Internal Urethrotomy (DVIU) or open reconstruction known as urethroplasty (1-6). The purpose of this study is to determine feasibility of endoscopic-only repair of urethral stricture or bladder neck contracture using a combination of existing surgical techniques of internal urethrotomy (or bladder neck incision) augmented by buccal mucosal graft.
Detailed Description
Background and Rationale There are two definitive treatment options for urethral strictures: DVIU and open urethroplasty. DVIU is an endoscopic procedure considered to be minimally invasive, but also with a high failure rate of 60-92%. The repeated DVIUs are reported to have even higher failure rates. On the other hand, open urethroplasty, considered a gold standard for reconstruction, is invasive, requires incision of the perineum or urethra, leaves a life-long scar, and has long term success rates of 74-95%. The details of DVIU and open urethroplasty are discussed below.
DVIU involves passing a cystoscope into the urethra to the level of stricture and incising the stricture longitudinally to create a wide passage to the level of normal urethra on the proximal side. The hope is to cut through the scar to the level of healthy underlying tissue and in the process of healing to populate the cut surface with healthy urethral epithelium (or at least to stabilize the scar in open configuration). In most cases, the scarring recurs faster than epithelization and most strictures recur after DVIU within 7-8 months. Studies show the strictures after traditional repeat DVIU are longer and require more involved reconstruction than strictures in patients without prior instrumentation.
Open urethroplasty for urethral strictures or bladder neck contractures usually involves longitudinal incision of the urethra (from outside in) and augmentation of the incised part with a strip of harvested Buccal Mucosal Graft (BMG). The goal of the operation is to create a wide urethral lumen for the patient to be able to pass urine without obstruction.
The first step of the procedure for DVIU and open reconstruction are nearly the same: a longitudinal incision of the scarred portion of the urethra. The difference is in the second part: covering the defect with buccal mucosal graft as in open urethroplasty vs leaving the incision uncovered and exposed to passage of urine.
Investigators of this study hereby propose to combine the minimally invasive technique of the DVIU with the technique of augmenting the incised stricture (or bladder neck contracture) using buccal mucosal graft placed endoscopically by means of application of liquid suspended graft. A similar, but more invasive technique was reported by Seith et al in 2012 performed in 12 patients with the exception of need for small open perineal incision for graft fixation. A purely endoscopic skin graft placement into urethra was reported by Naude in 1998 in 53 patients with 95% success rate at 2 years follow up. While he has not made actual incisions, his approach required percutaneous perineal needle placement for graft delivery and a specialized device for graft delivery and graft fixation. The procedure proposed for current trial is purely endoscopic with buccal graft placement and fixation augmented by fibrin glue. This type of fibrin glue sealant is readily available and widely used in General Surgery, Plastic Surgery and in Urology specifically for urethral reconstruction). This will allow for significantly less invasive procedure, shorter procedure time, absence of traditional perineal incision or needle puncture, and earlier return home (same day vs 1-3 days), earlier catheter removal (5-7 days vs 21 days) and earlier return to regular activities (1 week vs 6 weeks).
Overall, the aim is to improve the outcomes of traditional endoscopic procedure while eliminating morbidity of the open reconstruction with added benefits of earlier convalescence and health care savings from decreased surgical morbidity and shortened hospital stay.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urethral Stricture
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
liquid buccal mucosa graft
Arm Type
Experimental
Arm Description
DVIU treated with liquid buccal mucosal graft; endoscopic injection of morcellated buccal mucosal graft mixed with fibrin glue
Intervention Type
Biological
Intervention Name(s)
DVIU treated with liquid buccal mucosal graft
Intervention Description
DVIU treated with liquid buccal mucosal graft; internal urethrotomy for urethral stricture followed by injection of morcellated buccal mucosal graft mixed with fibrin glue (Tisseel, Baxter)
Primary Outcome Measure Information:
Title
Voiding Surgical Outcomes: Stricture Recurrence
Description
The ultimate outcome of this procedure is number of patients successfully treated without need for re-intervention (such as need for urethral dilation, endoscopic manipulation or open reconstruction). Recurrence of stricture will be reported as number of events. To detect stricture recurrence, patients will be monitored with: peak urine flow (milliliters per second) and post-void residuals (milliliters) and will be assessed post- operatively at every visit up to three years Flexible cystoscopy will be offered to patients at one year follow up or at any time point if there is suspicion of stricture recurrence based on patients complaints (reported as number of recurrences).
Time Frame
3 years
Secondary Outcome Measure Information:
Title
Immediate Perioperative Outcomes
Description
This is a composite outcome measure consisting of the following measures: duration of surgery (time in minutes), immediate postoperative complications: bleeding requiring blood transfusion (units of transfused blood), cerebrovascular complications reported as number of events (stroke, myocardial infarctions, pulmonary emboli) , problems with anesthesia (inability to extubate, need to re-intubate reported as number of each events), allergic reactions including anaphylaxis (number) and, duration of hospital stay (days).
Time Frame
Day of surgery
Title
Short-term Postoperative Outcomes
Description
This is a composite outcome measure consisting of the following measures: Urinary Tract Infection (number of infections requiring treatment), Sepsis (number of events), unscheduled ER visits (number), readmissions for hospital stay (number of events).
Time Frame
Up to 90 days
Title
Patient Satisfaction
Description
Global Response Assessment questionnaire will be given to patients at every visit to assess overall satisfaction with the procedure.
Time Frame
Post-operative up to 3 years follow up
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male >18 years of age
bulbar urethral stricture
bladder neck contracture
Exclusion Criteria:
<18 years old
developmental delay
incarcerated individuals,
history of prior urethroplasty
history of cerebrovascular diseases (prior stroke, MI)
history of deep vein thrombosis
history of pulmonary embolism
history of clotting disorders
factor 5 Leiden
antiphospholipid antibody syndrome
prothrombin gene mutation
protein S deficiency
protein C deficiency
dysfibrinogenemia
polycythemia vera
essential thrombocytosis
untreated malignancy
hypercoagulable state
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dmitriy Nikolavsky, MD
Phone
315-464-1500
Email
nikolavd@upstate.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Janice Sell
Phone
315-464-6114
Email
sellj@upstate.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dmitriy Nikolavsky, MD
Organizational Affiliation
State University of New York - Upstate Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
SUNY Upstate Medical University
City
Syracuse
State/Province
New York
ZIP/Postal Code
13210
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Liquid Buccal Mucosa Graft Urethroplasty
We'll reach out to this number within 24 hrs